ERBB2 and breast cancer: The study has also opened up a new potential avenue of improving the effectiveness of Trastuzumab (Herceptin), which currently benefits less than 30% of breast cancer bearing patients and as Trastuzumab-associated chemotherapy can modulate the pro-inflammatory markers of HER2-positive breast cancer patients [97].